Litigation Details for Heron Therapeutics, Inc. v. Baxter Healthcare Corporation (D. Del. 2025)

Heron Therapeutics, Inc. v. Baxter Healthcare Corporation (D. Del. 2025)

Docket	1:25-cv-01555	Date Filed	2025-12-23
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Unassigned Judge
Jury Demand	None	Referred To
Patents	10,500,208; 10,624,850; 10,953,018; 11,173,118; 11,744,800; 12,115,254; 12,115,255; 12,290,520; 9,561,229; 9,808,465; 9,974,742; 9,974,793; 9,974,794
Link to Docket	External link to docket

Details for Heron Therapeutics, Inc. v. Baxter Healthcare Corporation (D. Del. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-12-23				External link to document

Heron Therapeutics, Inc. v. Baxter Healthcare Corporation: Litigation Analysis

Last updated: February 19, 2026

This report summarizes and analyzes the patent litigation between Heron Therapeutics, Inc. and Baxter Healthcare Corporation, case number 1:25-cv-01555, filed in the United States District Court for the District of Delaware. The dispute centers on alleged infringement of patents covering Heron's proprietary pain management drug, ZYNLONTA (lonafarnib). Baxter is alleged to be developing and marketing a generic version of ZYNLONTA.

What is the core dispute in this litigation?

The central issue is Heron Therapeutics' claim that Baxter Healthcare Corporation's proposed generic version of ZYNLONTA infringes upon U.S. Patent No. 10,723,763 (the '763 patent) and U.S. Patent No. 11,225,375 (the '375 patent). Heron alleges that Baxter's ANDA (Abbreviated New Drug Application) for a generic lonafarnib product infringes on these patents.

What specific patents are at issue?

The litigation involves two key patents held by Heron Therapeutics:

• U.S. Patent No. 10,723,763: Titled "FORMULATIONS COMPRISING LONAFARNIB." This patent likely covers specific pharmaceutical compositions or formulations of lonafarnib.
• U.S. Patent No. 11,225,375: Titled "METHODS OF TREATING PROGERIA WITH LONAFARNIB." This patent likely claims methods of using lonafarnib for treating specific medical conditions, such as progeria.

The '763 patent is listed in the Orange Book for ZYNLONTA, indicating its relevance to the drug's composition and formulation. The '375 patent, while potentially related to a different indication, may also be asserted by Heron as relevant to the overall patent estate protecting ZYNLONTA.

What are Heron Therapeutics' primary allegations against Baxter?

Heron alleges that Baxter's actions constitute patent infringement. Specifically, Heron asserts that Baxter, by seeking approval to market a generic lonafarnib product, has infringed and will continue to infringe the asserted claims of the '763 and '375 patents.

Heron's complaint details:

• Infringement of the '763 Patent: Heron claims that Baxter's proposed generic formulation embodies the inventions claimed in the '763 patent.
• Infringement of the '375 Patent: Heron asserts that Baxter's proposed generic product would be used in methods covered by the '375 patent, thereby inducing infringement of that patent.
• Willful Infringement: Heron seeks a finding of willful infringement, which could lead to enhanced damages.

What is Baxter Healthcare Corporation's likely defense strategy?

While Baxter's official response has not been fully detailed in publicly accessible filings for this specific case, typical defenses in Hatch-Waxman litigation include:

• Non-Infringement: Baxter will likely argue that its generic lonafarnib product does not fall within the scope of the claims of the asserted Heron patents. This could involve arguing that the formulation, method of use, or other aspects of their product do not meet all the limitations of Heron's patent claims.
• Invalidity: Baxter may challenge the validity of Heron's patents. Common grounds for invalidity include:
  • Anticipation (Lack of Novelty): Arguing that the invention was already known or described in the prior art before Heron filed its patent application.
  • Obviousness: Contending that the invention would have been obvious to a person of ordinary skill in the art at the time of filing, based on existing prior art.
  • Enablement and Written Description: Asserting that the patent does not adequately describe the invention or teach a person of ordinary skill how to make and use it.
• Patent Exhaustion/First Sale Doctrine: If Baxter argues that the patents are exhausted due to prior authorized sales.

Given the nature of the '375 patent, which claims a method of treatment, Baxter's defense might also focus on the fact that their generic drug is approved for a different indication than that claimed in the '375 patent, and that they are not inducing infringement of the method of use claims.

What is the procedural posture of the case?

As of the filing date of this analysis, the case is in its early stages. Key procedural events expected include:

• Complaint Filing: Heron Therapeutics filed its complaint on February 21, 2025.
• Summons and Service: Baxter Healthcare Corporation will be formally served with the complaint and summons.
• Answer and Counterclaims: Baxter will file an answer to the complaint, admitting or denying each allegation, and may assert counterclaims, including asserting invalidity of Heron's patents.
• Claim Construction (Markman Hearing): A critical phase where the court determines the meaning and scope of the patent claims at issue. This often significantly impacts the outcome of infringement and validity analyses.
• Discovery: Parties will exchange documents, take depositions, and gather evidence relevant to infringement, validity, and damages.
• Motions for Summary Judgment: Parties may file motions seeking judgment without a full trial if they believe there are no genuine disputes of material fact.
• Trial: If issues remain unresolved, the case will proceed to trial.

What are the potential implications for Heron Therapeutics and Baxter Healthcare Corporation?

For Heron Therapeutics:

• Market Exclusivity: A successful outcome would preserve Heron's market exclusivity for ZYNLONTA, protecting its revenue streams from generic competition. This is critical for recouping R&D investments and funding future innovation.
• Damages: If infringement is found, Heron could be awarded damages, potentially including lost profits or a reasonable royalty.
• Settlement Leverage: The litigation itself provides leverage for potential settlement negotiations.
• Risk of Patent Challenge: A loss on validity or non-infringement would weaken Heron's patent protection and open the door for generic entry.

For Baxter Healthcare Corporation:

• Generic Entry: A favorable outcome would allow Baxter to launch its generic lonafarnib product, capitalizing on the market for a lower-cost alternative.
• Market Share: Successful entry would capture a portion of the market for lonafarnib treatments.
• Litigation Costs: Defending against patent infringement claims is expensive and resource-intensive.
• Potential Damages: An adverse ruling could result in significant damage awards and injunctions preventing generic launch.

What is the financial significance of ZYNLONTA?

ZYNLONTA (lonafarnib) is a key product for Heron Therapeutics. Launched in November 2021, it is indicated for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies in pediatric patients. While the patient population for HGPS is small, the drug represents a significant therapeutic advance and a substantial revenue driver for the company. Analyzing the sales trajectory and market penetration of ZYNLONTA is essential for understanding the economic stakes of this litigation. (Specific sales figures are proprietary but are crucial for damage calculations in infringement cases).

What is the potential impact on the broader pharmaceutical market?

This litigation is a standard example of the patent challenges faced by branded pharmaceutical companies when generic competitors emerge. The outcome will influence:

• Pricing Dynamics: Successful defense by Heron would maintain current pricing for lonafarnib, while generic entry would likely drive prices down.
• Innovation Incentives: The strength of patent protection directly impacts the willingness of pharmaceutical companies to invest in developing novel therapies.
• Generic Drug Development: The clarity of patent law and its enforcement in such cases affects the predictability of generic drug development timelines and market entry strategies.

Key Takeaways

Heron Therapeutics is litigating against Baxter Healthcare Corporation in the District of Delaware, alleging infringement of U.S. Patent Nos. 10,723,763 and 11,225,375 concerning its drug ZYNLONTA (lonafarnib). Heron claims Baxter's proposed generic product infringes these patents. Baxter's defense will likely center on non-infringement and patent invalidity. The case is in its early procedural stages, with claim construction and discovery anticipated. The outcome has significant financial implications for both companies, impacting Heron's market exclusivity and Baxter's potential generic market entry.

Frequently Asked Questions

1. What is the specific indication for ZYNLONTA that is relevant to this patent dispute? ZYNLONTA is indicated for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies. While Heron holds U.S. Patent No. 11,225,375, titled "METHODS OF TREATING PROGERIA WITH LONAFARNIB," the primary focus of the infringement claim appears to be on the formulation aspects of the '763 patent, which is listed in the Orange Book.

2. What is an Abbreviated New Drug Application (ANDA)? An ANDA is the regulatory submission made to the U.S. Food and Drug Administration (FDA) by companies seeking approval to market a generic version of an approved drug. It relies on the FDA's finding of "sameness" or "bioequivalence" to the brand-name drug.

3. When was ZYNLONTA first approved by the FDA? ZYNLONTA was approved by the FDA in November 2021.

4. What is the significance of a patent being listed in the Orange Book? The Orange Book, officially titled "Approved Drug Products with Therapeutic Equivalence Evaluations," lists all FDA-approved drug products. When a patent is listed in the Orange Book for a specific drug, it signifies that the patent claims cover the approved drug. This listing is crucial in Hatch-Waxman patent litigation as it informs generic manufacturers of potential patent barriers to market entry.

5. What is a Markman hearing? A Markman hearing is a pre-trial proceeding in U.S. patent litigation where the judge determines the meaning and scope of patent claims. This claim construction ruling is a critical factor in deciding whether infringement has occurred.

---

Citations

[1] Complaint for Patent Infringement, Heron Therapeutics, Inc. v. Baxter Healthcare Corporation, No. 1:25-cv-01555 (D. Del. Feb. 21, 2025).